NEW RESEARCH: Pressure BioSciences On the Move

Posted by Laura Swartz

September 29, 2014 at 9:56 AM

This morning we published a 16-page Quarterly Update on laboratory instrumentation company, Pressure BioSciences, Inc. (PBIO-OTC). 

Read More

Topics: Pressure BioSciences

At 1:00 PM ET TODAY, Truett-Hurst call and webcast for fiscal 2014 results

Posted by Laura Swartz

September 26, 2014 at 12:49 PM

At 1:00 PM ET, join Truett-Hurst, Inc. (THST-NASDAQ) conference call and webcast for fiscal 2014 results. The winemaker announced that it will conduct a conference call to discuss its fiscal 2014 results for the period ended on June 30, 2014, on Friday, September 26, 2014 at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time. The company's fiscal 2014 results for the period ended on June 30, 2014, were reported on September 25, 2014, prior to this call. The call is open on a listen-only basis to any interested parties and will be hosted by Mr. Phillip L. Hurst, Chief Executive Officer, and Mr. Paul Forgue, Chief Financial Officer and Chief Operations Officer.

Read More

Topics: Truett-Hurst

Boston Therapeutics Strengthens its Medical Advisory Board

Posted by Samy Goldfarb

September 24, 2014 at 9:55 AM

Boston Therapeutics, Inc. (BTHE-OTCQB), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed Meng Hee Tan, M.D. to serve as its Consulting Medical Director and a member of its Medical Advisory Team. Dr. Tan is expected to help guide the Company's development of its diabetes-related treatments.

Read More

Topics: BTHE

Truett-Hurst to Launch Single-Serving Wine Beverages Through Kroger

Posted by Karen Goldfarb

September 23, 2014 at 12:14 PM

Truett-Hurst Inc. (THST-NASDAQ) announced this morning that it will release ready-to-drink wine-based beverages in cans under the brand California Winecraft through Kroger’s supermarkets and multi-department stores. Kroger, one of the world's largest retailers, serves customers in 2,638 supermarkets and multi-department stores in 34 states and the District of Columbia under two dozen local banner names: Kroger, City Market, Dillons, Food 4 Less, Fred Meyer, Fry's, Harris Teeter, Jay C, King Soopers, QFC, Ralphs, and Smith's, among others. This particular line of products offers new flavor and packaging alternatives.

Headquartered in Healdsburg, California (Sonoma County wine country), Truett-Hurst's California Winecraft line of products adds to its current line of packaging innovations, which includes: California Square, PaperBoy, and Wrapped Wines. The California Winecraft line of wine-based beverages is flavored by unique recipes developed by in-house winemaker, Ms. Virginia Lambrix, with the cans bringing easy accessibility to some popular wine-based drinks, such as Sangria, Calimocho, and Wine Spritzers.

Read More

Topics: Truett-Hurst

Saleen Takes Orders for New 2015 Mustang (pictures & specs)

Posted by Laura Swartz

September 23, 2014 at 11:28 AM

Saleen Automotive, Inc. (SLNN-OTC) has been receiving a lot of press lately for its innovative take on the future of electric vehicles through the launch of the all-electric, high-performance Saleen FOURSIXTEEN. This week, however, Steve Saleen reminds us that he knows and has built a company on Mustangs and American Muscle cars. The company held its annual car show this past weekend at the Saleen headquarters in Corona, California, where a highlight of the event was the release of renderings for its newest Mustang: the 2015 Saleen 302.

Read More

Topics: Saleen

Boston Therapeutics Signs Agreement for Phase III Study of BTI-320

Posted by Samy Goldfarb

September 22, 2014 at 3:41 PM

Boston Therapeutics, Inc. (BTHE-OTCQB), a developer of complex carbohydrate therapeutics to treat diabetes, announced that it signed a clinical trial agreement with the prestigious Joslin Diabetes Center in Boston to be the lead clinic for the Company’s Phase III study of its candidate BTI-320.

BTI-320, a new generation of alpha glucosidase inhibitor, is a non-systemic chewable tablet designed to reduce post-meal elevation of blood glucose. BTI-320 is designed to be taken before meals and works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down carbohydrates into glucose and release it into the bloodstream.

Read More

Topics: BTHE

Total Wine & More Adding More Truett-Hurst Wines to Shelves

Posted by Karen Goldfarb

September 19, 2014 at 12:34 PM

California winemaker Truett-Hurst, Inc. (THST-NASDAQ) has announced that, starting Fall 2014 and Spring 2015, beverage retail company Total Wine & More will be adding more of Truett-Hurst's new wines to its retail selection. This news follows Truett-Hurst's announcement last month that grocery retailer Safeway was also adding moreTruett-Hurst wines to its listings, starting in September 2014.

Read More

Topics: Truett-Hurst

Amarantus BioScience Outlines Required Steps for Eltoprazine Trial

Posted by Laura Swartz

September 17, 2014 at 3:11 PM

Amarantus BioScience Holdings, Inc. (AMBS-OTC) provided investors with an important update today regarding the company's plans to initiate a Phase 2b clinical study of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia, or PD-LID.

Read More

Topics: AMBS, Amarantus

Clinical Trial Finds Link Between Xanax, Valium and Alzheimer's Disease

Posted by Laura Swartz

September 10, 2014 at 2:54 PM

A new clinical study published Tuesday in the British Medical Journal, identified a possible link between long-term use of benzodiazepines and Alzheimer's disease. Researchers examined close to 1,800 Alzheimer's patients who had at least six years of medical data and who had used benzodiazepines at least five years before their Alzheimer's diagnosis, and compared these cases to over 7,100 control patients. All medical records used in the study were from patients over 66 years of age.

Read More

Topics: Amarantus

NEW RESEARCH: Amarantus Pursues Novel Blood Test for Alzheimer's and More

Posted by Laura Swartz

September 8, 2014 at 11:58 AM

Today, Crystal Research Associates has issued a 76-page Executive Informational Overview® (EIO) on California biopharmaceutical company Amarantus BioScience Holdings, Inc. (AMBS-OTC). The EIO details the Company's pipeline development, business model, growth strategies, market opportunities, potential milestones, competitive landscape, financial position, business risks, and more. It is available for download on our website here. A summary of Amarantus' 12 competitive advantages in its target diagnostics and therapeutics fields is available here: Amarantus' Key Points.

Read More

Topics: Amarantus

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Topic